Yu-Hao XueYu-Shin PengHsin-Fu TingJason Peijer HsiehYu-Kai HuangYu-Hsun WangJeng-Yuan ChiouJames Cheng-Chung Wei2026-01-292026-01-29201810.1159/000485176https://scholars.csmu.edu.tw/handle/123456789/3725<jats:p><b><i>Introduction:</i></b> This population-based cohort study investigates the association between osteoarthritis (OA) and dementia as well as the connection between NSAIDs and dementia. <b><i>Methods:</i></b> We chose the samples from the Taiwan Longitudinal Health Insurance Database and then divided them into two groups, which were then matched 1: 1 by propensity score. The first group was the OA group that contained patients with newly diagnosed OA and the second group was the non-OA group. We used the χ<sup>2</sup> test, Student <i>t</i> test, Kaplan-Meier analysis, and Cox proportional hazard model for different purposes. <b><i>Results:</i></b> The prevalence of dementia in the OA group was higher than that in the non-OA group. The adjusted hazard ratio of the former was 1.42 (95% CI, 1.30–1.54). We also found that etoricoxib and diclofenac might reduce the incidence of dementia. <b><i>Conclusion:</i></b> Patients with OA might have a higher risk of dementia. Both etoricoxib and diclofenac might lower the risk of dementia in patients with OA.</jats:p>[SDGs]SDG3Etoricoxib and Diclofenac Might Reduce the Risk of Dementia in Patients with Osteoarthritis: A Nation-Wide, Population-Based Retrospective Cohort Studyjournal-article